There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Array Biopharma (NASDAQ:ARRY), Audentes Therapeutics (NASDAQ:BOLD) and Loxo Oncology (NASDAQ:LOXO) with bullish sentiments.
Array Biopharma (ARRY)
Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Array Biopharma yesterday and set a price target of $22. The company’s shares closed on Friday at $13.98.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 4.7% and a 34.2% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
Currently, the analyst consensus on Array Biopharma is a Strong Buy with an average price target of $24.25.
See today’s analyst top recommended stocks >>
Audentes Therapeutics (BOLD)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Audentes Therapeutics yesterday. The company’s shares closed on Friday at $36.64.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 28.7% and a 51.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $40, which is a 9.2% upside from current levels. In a report issued on September 25, H.C. Wainwright also maintained a Buy rating on the stock with a $40 price target.
.
Loxo Oncology (LOXO)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on Loxo Oncology yesterday. The company’s shares closed on Friday at $159.60.
According to TipRanks.com, Frahm is a 2-star analyst with an average return of 0.5% and a 41.7% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Blueprint Medicines, and Incyte Corp.
Loxo Oncology has an analyst consensus of Strong Buy, with a price target consensus of $199.14, representing a 24.8% upside. In a report issued on September 24, Leerink Partners also initiated coverage with a Buy rating on the stock with a $205 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
